Glucocorticosteroid therapy for multiple sclerosis: a critical review

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Glucocorticosteroids (GCS) are widely used in multiple sclerosis (MS) therapy, but their optimal use remains controversial.
• New disease-modifying treatments for MS necessitate a re-evaluation of GCS cost-benefit.
• Understanding GCS mechanisms is crucial for optimizing MS treatment strategies.

Purpose of the Study:

• To review the cellular and molecular mechanisms of GCS action in the context of MS pathophysiology.
• To critically evaluate the therapeutic efficacy of GCS in different MS scenarios.
• To inform current debates on GCS use in MS management.

Main Methods:

• Literature review of GCS mechanisms of action in MS.
• Critical analysis of clinical studies on GCS for MS exacerbations.
• Evaluation of GCS use in preventing MS onset after optic neuritis.
• Assessment of GCS impact on sustained disability progression in MS.

Main Results:

• GCS exert immunomodulatory and anti-inflammatory effects relevant to MS.
• Evidence supports GCS for improving recovery from MS exacerbations.
• GCS may delay MS onset after optic neuritis, but long-term benefits require further study.
• The role of GCS in delaying sustained disability progression in established MS is less clear.

Conclusions:

• Glucocorticosteroids remain important in managing MS exacerbations.
• Further research is needed to clarify the long-term benefits and optimal use of GCS in MS.
• Cost-benefit analyses should guide the integration of GCS with newer MS therapies.